Calidi Biotherapeutics (CLDI) Stock Statistics & Valuation Metrics

Calidi Biotherapeutics has a market cap or net worth of $2.63M. The enterprise value is -$1.86M.

Calidi Biotherapeutics has 10,895,725 shares outstanding. The number of shares has decreased by -2.65% in one year.

Calidi Biotherapeutics’s return on equity (ROE) is -5.30 and return on invested capital (ROIC) is -314.38%.

The current PE Ratio of Calidi Biotherapeutics is ―. Calidi Biotherapeutics’s PEG ratio is 0.00303.

In the last 12 months, Calidi Biotherapeutics had revenue of 0.00 and earned -19.91M in profits. Earnings per share was -5.95.

In the last 12 months, operating cash flow was -21.29M and capital expenditures -120.00K, giving a free cash flow of -21.41M billion.

Calidi Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Calidi Biotherapeutics upcoming earnings date is May 20, 2026, After Close (Confirmed).

Calidi Biotherapeutics as a current ratio of 1.59, with Debt / Equity ratio of 52.25%

In the past 12 months, Calidi Biotherapeutics has paid 15.00K in taxes.

Calidi Biotherapeutics EV to EBITDA ratio is -0.11, with an EV/FCF ratio of -0.09.

Calidi Biotherapeutics has $5.60M in cash and marketable securities with $1.96M in debt, giving a net cash position of $3.64M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Calidi Biotherapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―